Expected plasma concentrations of dabigatran or rivaroxaban after treatment
| Drug . | Cpeak (range) . | Ctrough (range) . |
|---|---|---|
| Dabigatran* | 175 ng/mL (117-275 ng/mL) | 91 ng/mL (61-143 ng/mL) |
| Rivaroxaban† | 215 ng/mL (22-535 ng/mL) | 32 ng/mL (6-239 ng/mL) |
| Drug . | Cpeak (range) . | Ctrough (range) . |
|---|---|---|
| Dabigatran* | 175 ng/mL (117-275 ng/mL) | 91 ng/mL (61-143 ng/mL) |
| Rivaroxaban† | 215 ng/mL (22-535 ng/mL) | 32 ng/mL (6-239 ng/mL) |
Steady-state geometric mean dabigatran plasma concentration (25th-75th percentile range) measured around 2 hours (Cpeak) or 12 hours (Ctrough) after 150 mg dabigatran administration twice daily.10 Dilute thrombin clotting time or ECT at Cpeak are approximately prolonged 2 or 3 times the baseline value, respectively.8 Between-reagent variability should be considered when interpreting results.
Steady-state geometric mean rivaroxaban plasma concentration (90% prediction interval) measured around 2 hours (Cpeak) or 24 hours (Ctrough) after 20 mg rivaroxaban administration once daily.17 PT at Cpeak is approximately prolonged 1.5 times the baseline value.16,19 Between-reagent variability should be considered when interpreting results.16,19,26,30